{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:21:55Z","timestamp":1769764915727,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.jacl.2015.01.008","type":"journal-article","created":{"date-parts":[[2015,1,30]],"date-time":"2015-01-30T12:45:03Z","timestamp":1422621903000},"page":"343-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Is HPS2-THRIVE the death knell for niacin?"],"prefix":"10.1016","volume":"9","author":[{"given":"Peter P.","family":"Toth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3722-4345","authenticated-orcid":false,"given":"Avinash M.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandeep S.","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Boden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2015.01.008_bib1","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.01.008_bib2","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.01.008_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.01.008_bib4","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.01.008_bib5","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.01.008_bib6","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Armitage","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.01.008_bib7","first-page":"S3","article-title":"Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting","volume":"14","author":"Cziraky","year":"2008","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.jacl.2015.01.008_bib8","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey","volume":"287","author":"Ford","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.01.008_bib9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"issue":"Suppl A","key":"10.1016\/j.jacl.2015.01.008_bib10","first-page":"5A","article-title":"Cholesterol and lipids in the risk of coronary artery disease\u2013the Framingham Heart Study","volume":"4","author":"Castelli","year":"1988","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacl.2015.01.008_bib11","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJM199006143222403","article-title":"Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease","volume":"322","author":"Pekkanen","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.01.008_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2006.04.006","article-title":"Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation","volume":"98","author":"Wolfram","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.01.008_bib13","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0002-9149(99)80761-9","article-title":"Distribution of lipids in 8,500\u00a0men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group","volume":"75","author":"Rubins","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.01.008_bib14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.01.008_bib15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.jacl.2015.01.008_bib16","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/BF03216290","article-title":"Coronary drug project: experience with niacin. Coronary Drug Project Research Group","volume":"40","author":"Berge","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2015.01.008_bib17","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.01.008_bib18","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens","volume":"264","author":"Kane","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.01.008_bib19","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.01.008_bib20","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.01.008_bib21","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima\u2013media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.01.008_bib22","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jacc.2013.07.023","article-title":"Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglycerides and Impact on Global Health Outcomes)","volume":"62","author":"Guyton","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.01.008_bib23","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1053\/euhj.2000.2515","article-title":"Platelet activation: assessment and quantification","volume":"22","author":"Kamath","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.01.008_bib24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.atherosclerosis.2003.07.003","article-title":"Antiatherothrombotic effects of nicotinic acid","volume":"171","author":"Rosenson","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.01.008_bib25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.atherosclerosis.2008.08.003","article-title":"Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study","volume":"204","author":"Warnholtz","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.01.008_bib26","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/eurheartj\/eht064","article-title":"The difficult search for a \u2018partner\u2019 of statins in lipid-targeted prevention of vascular events: the re-emergence and fall of niacin","volume":"34","author":"Landmesser","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.01.008_bib27","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/ATVBAHA.109.201129","article-title":"Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids","volume":"30","author":"Wu","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2015.01.008_bib28","doi-asserted-by":"crossref","first-page":"46L","DOI":"10.1016\/S0002-9149(00)01470-3","article-title":"Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review","volume":"86","author":"Sprecher","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.01.008_bib29","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jacc.2012.10.030","article-title":"The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression","volume":"61","author":"Lavigne","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.01.008_bib30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.amjcard.2006.04.011","article-title":"Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease","volume":"98","author":"Kuvin","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.01.008_bib31","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.jacc.2013.07.051","volume":"62","author":"Acharjee","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.01.008_bib32","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.amjcard.2013.05.050","article-title":"Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry)","volume":"112","author":"Acharjee","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.01.008_bib33","article-title":"Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies","author":"Joshi","year":"2014","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2015.01.008_bib34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.tem.2014.05.005","article-title":"High-density lipoprotein subfractions: current views and clinical practice applications","volume":"25","author":"Martin","year":"2014","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jacl.2015.01.008_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/eurheartj\/ehu264","article-title":"HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative","volume":"36","author":"Martin","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.01.008_bib36","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.2174\/0929867321666140414103455","article-title":"Subfractions and subpopulations of HDL: an update","volume":"21","author":"Rizzo","year":"2014","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jacl.2015.01.008_bib37","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1194\/jlr.R036095","article-title":"Unraveling the complexities of the HDL lipidome","volume":"54","author":"Kontush","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.01.008_bib38","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1021\/pr100520x","article-title":"Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography","volume":"9","author":"Gordon","year":"2010","journal-title":"J Proteome Res"},{"key":"10.1016\/j.jacl.2015.01.008_bib39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.01.008_bib40","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.01.008_bib41","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jacc.2013.07.025","article-title":"The addition of niacin to\u00a0statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality","volume":"62","author":"Khera","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.01.008_bib42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1074248413514481","article-title":"The therapeutic role of niacin in dyslipidemia management","volume":"19","author":"Boden","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jacl.2015.01.008_bib43","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.01.008_bib44","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2337\/dc13-0790","article-title":"Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial","volume":"37","author":"Linz","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2015.01.008_bib45","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.amjcard.2014.01.426","article-title":"Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease","volume":"113","author":"Zambon","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.01.008_bib46","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.01.008_bib47","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jacl.2013.08.001","article-title":"High-density lipoproteins: a consensus statement from the National Lipid Association","volume":"7","author":"Toth","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.01.008_bib48","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.01.008_bib49","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.01.008_bib50","first-page":"(12S)","article-title":"Quantitative impact of remnant lipoproteins on risk for hard CHD events: a meta-analysis of the Framingham Offspring and Jackson Heart Studies","volume":"63","author":"Toth","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.01.008_bib51","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.01.008_bib52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia-full report","volume":"8","author":"Grundy","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.01.008_bib53","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacl.2015.01.008_bib54","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415000446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415000446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T18:51:11Z","timestamp":1537901471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287415000446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1933287415000446"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2015.01.008","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is HPS2-THRIVE the death knell for niacin?","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2015.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}